Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma
Introduction Neoadjuvant chemotherapy in high‐risk, locally advanced prostate cancer remains an understudied area of prostate cancer. Chemotherapy continues to be a viable option. The combination with surgery may be desired but lacks data for complete recommendation. Case presentation We demonstrate...
Gespeichert in:
| Veröffentlicht in: | IJU case reports 2019-03, Vol.2 (2), p.61-64 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 64 |
|---|---|
| container_issue | 2 |
| container_start_page | 61 |
| container_title | IJU case reports |
| container_volume | 2 |
| creator | Brunner, Robert Buck, Bradley Giffen, Zane Murtagh, Daniel Lewis, Terrence Gatto‐Weis, Cara Sindhwani, Puneet |
| description | Introduction
Neoadjuvant chemotherapy in high‐risk, locally advanced prostate cancer remains an understudied area of prostate cancer. Chemotherapy continues to be a viable option. The combination with surgery may be desired but lacks data for complete recommendation.
Case presentation
We demonstrate the successful utilization of chemotherapy in the neoadjuvant arena. A 70‐year‐old male was diagnosed with high‐risk prostate cancer on biopsy. Upon multiparametric magnetic resonance imaging, the patient had local rectal wall invasion and stage T4 N0 M0 after a negative bone scan. After treatment with androgen‐deprivation therapy and docetaxel, repeat multiparametric magnetic resonance imaging showed regression of rectal invasion. The patient elected for prostatectomy and avoided proctectomy and colostomy. The patient's postoperative prostate‐specific antigen was undetectable on initial follow‐up.
Conclusion
We show that neoadjuvant chemotherapy merits further study and may provide a more permanent surgical option for patients. |
| doi_str_mv | 10.1002/iju5.12031 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7292178</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IJU512031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2431-60ebe967ae515d4344e8aa0c4cb2e0caee399f514effacf482bd2e450882b03b3</originalsourceid><addsrcrecordid>eNp9kM1Kw0AQxxdRbKm9-ACSs9C6X-kmF6EUPypFLxa8LZPNpNnafLBJK735CD6jT2JqtNSLpxmY3_yG-RNyzuiQUcqv7HLtDxmngh2RLveVGjDFXo4P-g7pV9WSNjBlYiT5KekIrqQQSnbJ-BELiJfrDeS1Z1LMijpFB-XWSwrnpXaRfr5_OFu9eqUrqhpqazyIMS8MOGPzIoMzcpLAqsL-T-2R-e3N8-R-MHu6m07Gs4HhUrDBiGKE4UgB-syPpZASAwBqpIk4UgOIIgwTn0lMEjCJDHgUc5Q-DZqOikj0yHXrLddRhrHBvHaw0qWzGbitLsDqv5PcpnpRbLTiIWcqaASXrcA0n1QOk_0uo3qXpd5lqb-zbOCLw2t79De5BmAt8GZXuP1HpacPc7-VfgF-T4I5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Brunner, Robert ; Buck, Bradley ; Giffen, Zane ; Murtagh, Daniel ; Lewis, Terrence ; Gatto‐Weis, Cara ; Sindhwani, Puneet</creator><creatorcontrib>Brunner, Robert ; Buck, Bradley ; Giffen, Zane ; Murtagh, Daniel ; Lewis, Terrence ; Gatto‐Weis, Cara ; Sindhwani, Puneet</creatorcontrib><description>Introduction
Neoadjuvant chemotherapy in high‐risk, locally advanced prostate cancer remains an understudied area of prostate cancer. Chemotherapy continues to be a viable option. The combination with surgery may be desired but lacks data for complete recommendation.
Case presentation
We demonstrate the successful utilization of chemotherapy in the neoadjuvant arena. A 70‐year‐old male was diagnosed with high‐risk prostate cancer on biopsy. Upon multiparametric magnetic resonance imaging, the patient had local rectal wall invasion and stage T4 N0 M0 after a negative bone scan. After treatment with androgen‐deprivation therapy and docetaxel, repeat multiparametric magnetic resonance imaging showed regression of rectal invasion. The patient elected for prostatectomy and avoided proctectomy and colostomy. The patient's postoperative prostate‐specific antigen was undetectable on initial follow‐up.
Conclusion
We show that neoadjuvant chemotherapy merits further study and may provide a more permanent surgical option for patients.</description><identifier>ISSN: 2577-171X</identifier><identifier>EISSN: 2577-171X</identifier><identifier>DOI: 10.1002/iju5.12031</identifier><identifier>PMID: 32743374</identifier><language>eng</language><publisher>Australia: John Wiley and Sons Inc</publisher><subject>Case Report ; Case Reports ; docetaxel ; neoadjuvant chemotherapy ; prostate cancer ; prostatectomy ; prostatic adenocarcinoma</subject><ispartof>IJU case reports, 2019-03, Vol.2 (2), p.61-64</ispartof><rights>2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2431-60ebe967ae515d4344e8aa0c4cb2e0caee399f514effacf482bd2e450882b03b3</cites><orcidid>0000-0002-8490-6162</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292178/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292178/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32743374$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brunner, Robert</creatorcontrib><creatorcontrib>Buck, Bradley</creatorcontrib><creatorcontrib>Giffen, Zane</creatorcontrib><creatorcontrib>Murtagh, Daniel</creatorcontrib><creatorcontrib>Lewis, Terrence</creatorcontrib><creatorcontrib>Gatto‐Weis, Cara</creatorcontrib><creatorcontrib>Sindhwani, Puneet</creatorcontrib><title>Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma</title><title>IJU case reports</title><addtitle>IJU Case Rep</addtitle><description>Introduction
Neoadjuvant chemotherapy in high‐risk, locally advanced prostate cancer remains an understudied area of prostate cancer. Chemotherapy continues to be a viable option. The combination with surgery may be desired but lacks data for complete recommendation.
Case presentation
We demonstrate the successful utilization of chemotherapy in the neoadjuvant arena. A 70‐year‐old male was diagnosed with high‐risk prostate cancer on biopsy. Upon multiparametric magnetic resonance imaging, the patient had local rectal wall invasion and stage T4 N0 M0 after a negative bone scan. After treatment with androgen‐deprivation therapy and docetaxel, repeat multiparametric magnetic resonance imaging showed regression of rectal invasion. The patient elected for prostatectomy and avoided proctectomy and colostomy. The patient's postoperative prostate‐specific antigen was undetectable on initial follow‐up.
Conclusion
We show that neoadjuvant chemotherapy merits further study and may provide a more permanent surgical option for patients.</description><subject>Case Report</subject><subject>Case Reports</subject><subject>docetaxel</subject><subject>neoadjuvant chemotherapy</subject><subject>prostate cancer</subject><subject>prostatectomy</subject><subject>prostatic adenocarcinoma</subject><issn>2577-171X</issn><issn>2577-171X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp9kM1Kw0AQxxdRbKm9-ACSs9C6X-kmF6EUPypFLxa8LZPNpNnafLBJK735CD6jT2JqtNSLpxmY3_yG-RNyzuiQUcqv7HLtDxmngh2RLveVGjDFXo4P-g7pV9WSNjBlYiT5KekIrqQQSnbJ-BELiJfrDeS1Z1LMijpFB-XWSwrnpXaRfr5_OFu9eqUrqhpqazyIMS8MOGPzIoMzcpLAqsL-T-2R-e3N8-R-MHu6m07Gs4HhUrDBiGKE4UgB-syPpZASAwBqpIk4UgOIIgwTn0lMEjCJDHgUc5Q-DZqOikj0yHXrLddRhrHBvHaw0qWzGbitLsDqv5PcpnpRbLTiIWcqaASXrcA0n1QOk_0uo3qXpd5lqb-zbOCLw2t79De5BmAt8GZXuP1HpacPc7-VfgF-T4I5</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Brunner, Robert</creator><creator>Buck, Bradley</creator><creator>Giffen, Zane</creator><creator>Murtagh, Daniel</creator><creator>Lewis, Terrence</creator><creator>Gatto‐Weis, Cara</creator><creator>Sindhwani, Puneet</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8490-6162</orcidid></search><sort><creationdate>201903</creationdate><title>Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma</title><author>Brunner, Robert ; Buck, Bradley ; Giffen, Zane ; Murtagh, Daniel ; Lewis, Terrence ; Gatto‐Weis, Cara ; Sindhwani, Puneet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2431-60ebe967ae515d4344e8aa0c4cb2e0caee399f514effacf482bd2e450882b03b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Case Report</topic><topic>Case Reports</topic><topic>docetaxel</topic><topic>neoadjuvant chemotherapy</topic><topic>prostate cancer</topic><topic>prostatectomy</topic><topic>prostatic adenocarcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brunner, Robert</creatorcontrib><creatorcontrib>Buck, Bradley</creatorcontrib><creatorcontrib>Giffen, Zane</creatorcontrib><creatorcontrib>Murtagh, Daniel</creatorcontrib><creatorcontrib>Lewis, Terrence</creatorcontrib><creatorcontrib>Gatto‐Weis, Cara</creatorcontrib><creatorcontrib>Sindhwani, Puneet</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>IJU case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brunner, Robert</au><au>Buck, Bradley</au><au>Giffen, Zane</au><au>Murtagh, Daniel</au><au>Lewis, Terrence</au><au>Gatto‐Weis, Cara</au><au>Sindhwani, Puneet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma</atitle><jtitle>IJU case reports</jtitle><addtitle>IJU Case Rep</addtitle><date>2019-03</date><risdate>2019</risdate><volume>2</volume><issue>2</issue><spage>61</spage><epage>64</epage><pages>61-64</pages><issn>2577-171X</issn><eissn>2577-171X</eissn><abstract>Introduction
Neoadjuvant chemotherapy in high‐risk, locally advanced prostate cancer remains an understudied area of prostate cancer. Chemotherapy continues to be a viable option. The combination with surgery may be desired but lacks data for complete recommendation.
Case presentation
We demonstrate the successful utilization of chemotherapy in the neoadjuvant arena. A 70‐year‐old male was diagnosed with high‐risk prostate cancer on biopsy. Upon multiparametric magnetic resonance imaging, the patient had local rectal wall invasion and stage T4 N0 M0 after a negative bone scan. After treatment with androgen‐deprivation therapy and docetaxel, repeat multiparametric magnetic resonance imaging showed regression of rectal invasion. The patient elected for prostatectomy and avoided proctectomy and colostomy. The patient's postoperative prostate‐specific antigen was undetectable on initial follow‐up.
Conclusion
We show that neoadjuvant chemotherapy merits further study and may provide a more permanent surgical option for patients.</abstract><cop>Australia</cop><pub>John Wiley and Sons Inc</pub><pmid>32743374</pmid><doi>10.1002/iju5.12031</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-8490-6162</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2577-171X |
| ispartof | IJU case reports, 2019-03, Vol.2 (2), p.61-64 |
| issn | 2577-171X 2577-171X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7292178 |
| source | DOAJ Directory of Open Access Journals; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Case Report Case Reports docetaxel neoadjuvant chemotherapy prostate cancer prostatectomy prostatic adenocarcinoma |
| title | Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T07%3A32%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20chemotherapy%20for%20high%E2%80%90risk%20prostatic%20adenocarcinoma&rft.jtitle=IJU%20case%20reports&rft.au=Brunner,%20Robert&rft.date=2019-03&rft.volume=2&rft.issue=2&rft.spage=61&rft.epage=64&rft.pages=61-64&rft.issn=2577-171X&rft.eissn=2577-171X&rft_id=info:doi/10.1002/iju5.12031&rft_dat=%3Cwiley_pubme%3EIJU512031%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32743374&rfr_iscdi=true |